CSPC Pharmaceutical Focus on the Ascending Triangle
CSPC Pharmaceutical (1093), a drug maker, announced that 1Q net income rose 21.8% on year to 1.16 billion yuan and operating profit grew 0.6% to 1.16 billion yuan on revenue of 6.13 billion yuan, up 11.5%.
Share this:
CSPC Pharmaceutical (1093), a drug maker, announced that 1Q net income rose 21.8% on year to 1.16 billion yuan and operating profit grew 0.6% to 1.16 billion yuan on revenue of 6.13 billion yuan, up 11.5%.
After the announcement of 1Q result, the stock jumped 6%. However, the stock failed to close above the April high at HK$17.20. Currently, the stock eased around 3%.
Source: GAIN Capital, TradingView
On a daily chart, the stock remains trading within the ascending triangle. A upside breakout could mean the bullish reversal signal. Otherwise, A break below the rising trend line could signal a continuation of the previous down trend.
In fact, both 20-day and 50-day moving averages are flattening. The RSI is capped by a resistance level at 59, but supported by a rising trend line at same time. Both indicators would suggest the lack of momentum for the prices.
In this case, the reader should consider a neutral bias and focus on the breakout signal in the future.
A clear break above HK$17.20 (the high of April) could consider a rise to the next resistance level at HK$19.26 (the high of March.
In an alternative scenario, crossing below HK$15.00 (the previous low) might bring a return to $13.12 (the low of March).
After the announcement of 1Q result, the stock jumped 6%. However, the stock failed to close above the April high at HK$17.20. Currently, the stock eased around 3%.
Source: GAIN Capital, TradingView
On a daily chart, the stock remains trading within the ascending triangle. A upside breakout could mean the bullish reversal signal. Otherwise, A break below the rising trend line could signal a continuation of the previous down trend.
In fact, both 20-day and 50-day moving averages are flattening. The RSI is capped by a resistance level at 59, but supported by a rising trend line at same time. Both indicators would suggest the lack of momentum for the prices.
In this case, the reader should consider a neutral bias and focus on the breakout signal in the future.
A clear break above HK$17.20 (the high of April) could consider a rise to the next resistance level at HK$19.26 (the high of March.
In an alternative scenario, crossing below HK$15.00 (the previous low) might bring a return to $13.12 (the low of March).
CSPC Pharmaceutical (1093), a drug maker, announced that 1Q net income rose 21.8% on year to 1.16 billion yuan and operating profit grew 0.6% to 1.16 billion yuan on revenue of 6.13 billion yuan, up 11.5%.
After the announcement of 1Q result, the stock jumped 6%. However, the stock failed to close above the April high at HK$17.20. Currently, the stock eased around 3%.
Source: GAIN Capital, TradingView
On a daily chart, the stock remains trading within the ascending triangle. A upside breakout could mean the bullish reversal signal. Otherwise, A break below the rising trend line could signal a continuation of the previous down trend.
In fact, both 20-day and 50-day moving averages are flattening. The RSI is capped by a resistance level at 59, but supported by a rising trend line at same time. Both indicators would suggest the lack of momentum for the prices.
In this case, the reader should consider a neutral bias and focus on the breakout signal in the future.
A clear break above HK$17.20 (the high of April) could consider a rise to the next resistance level at HK$19.26 (the high of March.
In an alternative scenario, crossing below HK$15.00 (the previous low) might bring a return to $13.12 (the low of March).
After the announcement of 1Q result, the stock jumped 6%. However, the stock failed to close above the April high at HK$17.20. Currently, the stock eased around 3%.
Source: GAIN Capital, TradingView
On a daily chart, the stock remains trading within the ascending triangle. A upside breakout could mean the bullish reversal signal. Otherwise, A break below the rising trend line could signal a continuation of the previous down trend.
In fact, both 20-day and 50-day moving averages are flattening. The RSI is capped by a resistance level at 59, but supported by a rising trend line at same time. Both indicators would suggest the lack of momentum for the prices.
In this case, the reader should consider a neutral bias and focus on the breakout signal in the future.
A clear break above HK$17.20 (the high of April) could consider a rise to the next resistance level at HK$19.26 (the high of March.
In an alternative scenario, crossing below HK$15.00 (the previous low) might bring a return to $13.12 (the low of March).
The complete CFD trading experience
Award-winning platforms, competitive spreads, low commissions and dedicated support.
We live and breathe the markets and are dedicated to helping traders realise their ambitions as we continue to set the industry bar.
Economic calendar
Web Trader platform
Our sophisticated web-based platform is packed with features.
Related articles
S&P 500, Nasdaq, Dow Forecast: Rising Yields Test Rally Ahead of Nvidia, Fed 8 22 2026
S&P 500, Nasdaq and Dow test key technical levels as momentum fades, raising the risk of a deeper correction heading into a pivotal week.
GBP/USD, Dow Jones Forecast: Key Technical Scenarios to Watch
GBP/USD and the Dow Jones are approaching critical technical levels amid earning optimism, Fed rate hike expectations, US-Iran developments, and persistent geopolitical risks.
The U.S. Dollar Is Rising Again and Nasdaq Is Feeling It
Nasdaq, the U.S. Dollar Index and Federal Reserve expectations are driving market sentiment ahead of a pivotal FOMC meeting. Razan Hilal, StoneX Market Analyst, explains how rising expectations for a hawkish Federal Reserve, persistent U.S.-Iran tensions and key technical levels on the U.S. Dollar Index could influence currencies, equities and precious metals in the weeks ahead.
StoneX Europe Ltd may make third party material available on this website which may contain information included but not limited to the conditions of financial markets. The material is for information purposes only and does not contain, and should not be construed as containing, investment advice and/or investment recommendation and/or an investment research and/or an offer of or solicitation for any transactions in financial instruments; any decision to enter into a specific transaction shall be made by the client following an assessment by him/her of their situation.
StoneX Europe Ltd makes no representation or warranty and assumes no liability as to the accuracy or completeness of the information provided, nor any loss arising from any investment based on a recommendation, forecast or other information supplied. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. We are not under any obligation to update any such material. Any opinion made may be personal to the author and may not reflect the opinion of StoneX Europe Ltd.